UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2022.

 

Commission File Number 333-161157

 

BETTERLIFE PHARMA INC.

(Translation of registrant’s name into English)

 

1275 WEST 6TH AVENUE, #300

VANCOUVER, BC CANADA V6H 1A6

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒      Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)( 1): ____

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6‑K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6‑K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6‑K submission or other Commission filing on EDGAR.

 

 

 

 

Exhibits:

 

99.1

Management’s discussion and analysis

99.2

Financial statements

99.3

CEO certification

99.4

CFO certification

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BETTERLIFE PHARMA INC.

       
Date: June 29, 2022 By: /s/ Moira Ong

 

 

Name: Moira Ong

 
 

Title: Chief Financial Officer

 

 

 

3

BetterLife Pharma (QB) (USOTC:BETRF)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more BetterLife Pharma (QB) Charts.
BetterLife Pharma (QB) (USOTC:BETRF)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more BetterLife Pharma (QB) Charts.